JW Therapeutics closes USD100m Series B financing round

JW Therapeutics announced the completion of a US$100 million Series B round of financing, the investment was co-led by CPE and Mirae Asset, jointed by CR-CP Life Science Fund and Oriza Holdings, as well as existing investors including Loyal Valley Capital, Temasek, Sequoia Capital China, ARCH Venture Partners, Juno Therapeutics, a Bristol Myers Squibb company, and WuXi AppTec.

JW Therapeutics announced the completion of a US$100 million Series B round of financing, the investment was co-led by CPE and Mirae Asset, jointed by CR-CP Life Science Fund and Oriza Holdings, as well as existing investors including Loyal Valley Capital, Temasek, Sequoia Capital China, ARCH Venture Partners, Juno Therapeutics, a Bristol Myers Squibb company, and WuXi AppTec.

JW Therapeutics will use the proceeds to further advance the clinical trials of its lead product JWCAR029 (a CAR-T cell product targeting CD19), further build-out a pipeline, and gear up to establish commercialization capabilities to support product launch.

James Li, Co-Founder and CEO of JW Therapeutics, commented: “We are very pleased to welcome our new investors and, by working together, we hope to accelerate our product development and serve Chinese patients.”

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/06/12/jw-therapeutics-closes-usd100m-series-b-financing-round/.

Leave a Reply

Please Login to Comment